Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab + Olaparib in solid tumors with homologous recombination repair gene mutations after response/stable on Olaparib
2024-518069-89-00Phase 2Authorised
- Sponsor
- Centre Georges-François Leclerc
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab, tremelimumab and olaparib in Non-hematologic malignancy, sponsored by Centre Georges-François Leclerc. Planned start Oct 2024; status: authorised.
02
Drugs
durvalumabtremelimumabolaparib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2024-518069-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518069-89-00.